Feature binding deficits in subjective cognitive decline and in mild cognitive impairment

Alexander Koppara, Ingo Frommann, Alexandra Polcher, Mario A. Parra, Wolfgang Maier, Frank Jessen, Thomas Klockgether, Michael Wagner

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: Feature binding is a sensitive and specific cognitive marker for Alzheimer's disease (AD). Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are clinical categories associated with an increased risk for AD.

OBJECTIVE: To investigate whether the SCD and MCI group are impaired with regard to feature binding.

METHODS: The feature binding test was administered to memory clinic patients with either SCD (n = 19, mean MMSE: 29.2) or with MCI (n = 23, mean MMSE: 26.5), and to a group of healthy controls (HC, n = 23, mean MMSE: 29.0). Participants were assessed with the CERAD Plus neuropsychological test battery. Cognitive performance of the three groups was compared by ANCOVA with age, gender and education as covariates and planned contrasts.

RESULTS: Groups differed in the binding condition. Planned contrasts showed significant differences in adjusted means between HC and SCD (p = 0.003), as well as between HC and MCI (p <  0.0001).

DISCUSSION: The feature binding task detects subtle cognitive impairments in participants with SCD, who are unimpaired in traditional neuropsychological testing. This corroborates the use of feature binding tests in preclinical AD studies and suggests that specific cognitive deficits can be found in SCD. Future studies incorporating AD biomarkers and longitudinal follow-up are needed to further establish the clinical utility of feature binding.

LanguageEnglish
PagesS161-S170
Number of pages10
JournalJournal of Alzheimer's Disease
Volume48
Issue numbers1
DOIs
Publication statusPublished - 24 Sep 2015

Fingerprint

Alzheimer Disease
Cognitive Dysfunction
Neuropsychological Tests
Biomarkers
Education
Control Groups

Keywords

  • analysis of variance
  • cognitive dysfunction/classification
  • female
  • humans
  • male
  • memory disorders/diagnosis
  • mental status schedule
  • neuropsychological tests

Cite this

Koppara, Alexander ; Frommann, Ingo ; Polcher, Alexandra ; Parra, Mario A. ; Maier, Wolfgang ; Jessen, Frank ; Klockgether, Thomas ; Wagner, Michael. / Feature binding deficits in subjective cognitive decline and in mild cognitive impairment. In: Journal of Alzheimer's Disease. 2015 ; Vol. 48, No. s1. pp. S161-S170.
@article{e58900ca72f64e6c9ecd0274ad596e6e,
title = "Feature binding deficits in subjective cognitive decline and in mild cognitive impairment",
abstract = "BACKGROUND: Feature binding is a sensitive and specific cognitive marker for Alzheimer's disease (AD). Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are clinical categories associated with an increased risk for AD.OBJECTIVE: To investigate whether the SCD and MCI group are impaired with regard to feature binding.METHODS: The feature binding test was administered to memory clinic patients with either SCD (n = 19, mean MMSE: 29.2) or with MCI (n = 23, mean MMSE: 26.5), and to a group of healthy controls (HC, n = 23, mean MMSE: 29.0). Participants were assessed with the CERAD Plus neuropsychological test battery. Cognitive performance of the three groups was compared by ANCOVA with age, gender and education as covariates and planned contrasts.RESULTS: Groups differed in the binding condition. Planned contrasts showed significant differences in adjusted means between HC and SCD (p = 0.003), as well as between HC and MCI (p <  0.0001).DISCUSSION: The feature binding task detects subtle cognitive impairments in participants with SCD, who are unimpaired in traditional neuropsychological testing. This corroborates the use of feature binding tests in preclinical AD studies and suggests that specific cognitive deficits can be found in SCD. Future studies incorporating AD biomarkers and longitudinal follow-up are needed to further establish the clinical utility of feature binding.",
keywords = "analysis of variance, cognitive dysfunction/classification, female, humans, male, memory disorders/diagnosis, mental status schedule, neuropsychological tests",
author = "Alexander Koppara and Ingo Frommann and Alexandra Polcher and Parra, {Mario A.} and Wolfgang Maier and Frank Jessen and Thomas Klockgether and Michael Wagner",
year = "2015",
month = "9",
day = "24",
doi = "10.3233/JAD-150105",
language = "English",
volume = "48",
pages = "S161--S170",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "s1",

}

Koppara, A, Frommann, I, Polcher, A, Parra, MA, Maier, W, Jessen, F, Klockgether, T & Wagner, M 2015, 'Feature binding deficits in subjective cognitive decline and in mild cognitive impairment' Journal of Alzheimer's Disease, vol. 48, no. s1, pp. S161-S170. https://doi.org/10.3233/JAD-150105

Feature binding deficits in subjective cognitive decline and in mild cognitive impairment. / Koppara, Alexander; Frommann, Ingo; Polcher, Alexandra; Parra, Mario A.; Maier, Wolfgang; Jessen, Frank; Klockgether, Thomas; Wagner, Michael.

In: Journal of Alzheimer's Disease, Vol. 48, No. s1, 24.09.2015, p. S161-S170.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Feature binding deficits in subjective cognitive decline and in mild cognitive impairment

AU - Koppara, Alexander

AU - Frommann, Ingo

AU - Polcher, Alexandra

AU - Parra, Mario A.

AU - Maier, Wolfgang

AU - Jessen, Frank

AU - Klockgether, Thomas

AU - Wagner, Michael

PY - 2015/9/24

Y1 - 2015/9/24

N2 - BACKGROUND: Feature binding is a sensitive and specific cognitive marker for Alzheimer's disease (AD). Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are clinical categories associated with an increased risk for AD.OBJECTIVE: To investigate whether the SCD and MCI group are impaired with regard to feature binding.METHODS: The feature binding test was administered to memory clinic patients with either SCD (n = 19, mean MMSE: 29.2) or with MCI (n = 23, mean MMSE: 26.5), and to a group of healthy controls (HC, n = 23, mean MMSE: 29.0). Participants were assessed with the CERAD Plus neuropsychological test battery. Cognitive performance of the three groups was compared by ANCOVA with age, gender and education as covariates and planned contrasts.RESULTS: Groups differed in the binding condition. Planned contrasts showed significant differences in adjusted means between HC and SCD (p = 0.003), as well as between HC and MCI (p <  0.0001).DISCUSSION: The feature binding task detects subtle cognitive impairments in participants with SCD, who are unimpaired in traditional neuropsychological testing. This corroborates the use of feature binding tests in preclinical AD studies and suggests that specific cognitive deficits can be found in SCD. Future studies incorporating AD biomarkers and longitudinal follow-up are needed to further establish the clinical utility of feature binding.

AB - BACKGROUND: Feature binding is a sensitive and specific cognitive marker for Alzheimer's disease (AD). Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are clinical categories associated with an increased risk for AD.OBJECTIVE: To investigate whether the SCD and MCI group are impaired with regard to feature binding.METHODS: The feature binding test was administered to memory clinic patients with either SCD (n = 19, mean MMSE: 29.2) or with MCI (n = 23, mean MMSE: 26.5), and to a group of healthy controls (HC, n = 23, mean MMSE: 29.0). Participants were assessed with the CERAD Plus neuropsychological test battery. Cognitive performance of the three groups was compared by ANCOVA with age, gender and education as covariates and planned contrasts.RESULTS: Groups differed in the binding condition. Planned contrasts showed significant differences in adjusted means between HC and SCD (p = 0.003), as well as between HC and MCI (p <  0.0001).DISCUSSION: The feature binding task detects subtle cognitive impairments in participants with SCD, who are unimpaired in traditional neuropsychological testing. This corroborates the use of feature binding tests in preclinical AD studies and suggests that specific cognitive deficits can be found in SCD. Future studies incorporating AD biomarkers and longitudinal follow-up are needed to further establish the clinical utility of feature binding.

KW - analysis of variance

KW - cognitive dysfunction/classification

KW - female

KW - humans

KW - male

KW - memory disorders/diagnosis

KW - mental status schedule

KW - neuropsychological tests

UR - https://www.j-alz.com/

U2 - 10.3233/JAD-150105

DO - 10.3233/JAD-150105

M3 - Article

VL - 48

SP - S161-S170

JO - Journal of Alzheimer's Disease

T2 - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - s1

ER -